@entity5714 after XXXX therapy for @entity1072 .

@entity1 @entity137 @entity1072 @entity3118 @entity5714
PURPOSE: A report of the clinical features, treatment, and outcome of @entity1 who developed @entity5714 ( @entity5714 ) temporally associated with @entity3118 (Fludara; Berlex Laboratories, Richmond, CA) therapy for @entity1072 ( @entity1072 ). @entity1 AND METHODS: Data on 24 @entity1 who developed @entity5714 related to @entity3118 therapy were collected from the Spontaneous Reporting System of the Food and Drug Administration (FDA) and the Walter Reed Army Medical Center (Washington, DC). RESULTS: Seventeen (71%) @entity1 developed @entity5714 after either the first, second, or third cycle of this drug. The longest duration of @entity3118 therapy before @entity5714 occurred was six cycles. The median decline in hematocrit from baseline during the hemolytic episode was 14.1 (range, 8.0 to 28.9) for the 18 @entity1 for whom this information was available. For the 11 @entity1 for whom transfusion requirements were known, the number of transfusions administered ranged between three and 36. Seven (29%) @entity1 died of medical complications associated with the @entity5714 . Seven of eight @entity1 who were re-challenged with @entity3118 after an episode of @entity5714 developed recurrent @entity5714 , and three of these @entity1 died. CONCLUSION: @entity5714 associated with @entity3118 therapy appears to be uncommon, but it can be severe and fatal, especially if a @entity1 is re-treated with this drug after a previous episode of @entity5714 . The mechanism of this @entity137 is unknown, but it may be caused by the release of a suppressed auto-antibody to a native red cell antigen.
